Current Status and Challenges of CAR-T Immunotherapy in Hematologic Malignancies -Review / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 626-630, 2018.
Article
de Zh
| WPRIM
| ID: wpr-690938
Bibliothèque responsable:
WPRO
ABSTRACT
The chimeric antigen receptor (CAR) T cell therapy has gradually became a new trend in the treatment of refractory and relapsed hematologic malignancies by developing for 30 years. With the exciting development of genetic engineering, CAR-T technology has subjected to 4 generations of innovation. Structure of CAR-T started from a single signal molecule to 2 or more than 2 co-stimulatory molecules, and then coding the CAR gene or promoter. CAR-T can specifically recognize tumor antigens, and does not be restricted by major histocompatibility complex (MHC), thus making a breakthrough in clinical treatment. In this review, the history, structure and mechanism of action of CAR-T, as well as the current status and challenges of CAR-T immunotherapy in acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia and multiple myeloma are summarized.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Thérapeutique
/
Récepteurs aux antigènes des cellules T
/
Lymphocytes T
/
Immunothérapie adoptive
/
Antigènes CD19
/
Tumeurs hématologiques
/
Immunothérapie
Limites du sujet:
Humans
langue:
Zh
Texte intégral:
Journal of Experimental Hematology
Année:
2018
Type:
Article